Mejorando la eficacia del sorafenib con nanopartículas en el tratamiento del hepatocarcinoma: mini revisión
DOI:
https://doi.org/10.29105/qh14.04-507Palabras clave:
Carcinoma hepatocelular, nanopartículas, entrega de fármacosResumen
El hepatocarcinoma es el tipo de cáncer hepático más común y tiene un alto índice de mortalidad, este padecimiento se
detecta en la mayoría de los casos en los estados avanzados de la enfermedad. El tratamiento de primera línea en
hepatocarcinoma avanzado es el sorafenib, el cual, es un inhibidor de tirosin-cinasas que ayuda a aumentar la sobrevida de
los pacientes. Una de las razones por la cual la respuesta al sorafenib es baja, es debido a la resistencia que generan las células cancerígenas a este fármaco. La nanotecnología a ayudado a mejorar las características farmacocinéticas y
farmacodinámicas de los fármacos mediante el uso de nano acarreadores. En esta mini revisión se describirán los
mecanismos de acción antitumoral descritos para el sorafenib, los mecanismos de resistencia y como los nano acarreadores han mejorado la terapia con sorafenib al disminuir la resistencia y mejorar la entrega del fármaco en el sitio tumoral.
Descargas
Citas
- [1]. Aobuliaisan, K., Li, Q., Deng, C., Yang, F., Xie, Z., Jia, W., & Yin, D. (2025). ASGPR-targeted micelles co-delivering lenvatinib and COP1 siRNA for hepatocellular carcinoma via dual-targeting. European Journal of Pharmaceutical Sciences, 216, 107308. https://doi.org/10.1016/j.ejps.2025.107308. DOI: https://doi.org/10.1016/j.ejps.2025.107308
- [2]. Qu, Y., Chen, C., Sun, F., Liu, S., Zhao, G., Zhao, Z., Liu, C., Jiang, X., & Li, T. (2025). Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment. Nature Communications, 16(1), 7340. https://doi.org/10.1038/s41467-025-61974-w. DOI: https://doi.org/10.1038/s41467-025-61974-w
- [3]. Cisneros-Garza, L. E., González-Huezo, M. S., Moctezuma-Velázquez, C., Ladrón De Guevara-Cetina, L., Vilatobá, M., Garcia-Juárez, L., Alvarado-Reyes, R., Álvarez-Treviño, G. A., Allende-Pérez, S., Bornstein-Quevedo, L., Calderillo-Ruiz, G., Carrillo-Martinez, M. A., Castillo-Barradas, M., Cerda-Reyes, E., Félix-Leyva, J. A., Gabutti-Thomas, J. A., Guerrero-Ixtlahuac, J., Higuera-de-la-Tijera, F., Huitzil-Meléndez, D., ... Torrecillas-Torres, L. (2022). II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiologia y diagnóstico. Revista de Gastroenterología de México, 87(2), 216-234. https://doi.org/10.1016/j.rgmx.2021.10.002. DOI: https://doi.org/10.1016/j.rgmx.2021.10.002
- [4]. Reig, M., Forner, A., Ávila, M. A., Ayuso, C., Minguez, B., Varela, M., Bilbao, I., Bilbao, J. I., Burrel, M., Bustamante, J., Ferrer, J., Gómez, M. Á., Llovet, J. M., De La Mata, M., Matilla, A., Pardo, F., Pastrana, M. A., Rodriguez-Perálvarez, M., Tabernero, J.,... Bruix, J. (2021). Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH. Medicina Clínica, 156(9), 463.e1-463.e30. https://doi.org/10.1016/j.medcli.2020.09.022. DOI: https://doi.org/10.1016/j.medcli.2020.09.022
- [5]. Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, M., & Monsour, H. (2016). Hepatocellular carcinoma: A review. Journal of Hepatocellular Carcinoma, Volume 3, 41-53. https://doi.org/10.2147/JHC.S61146. DOI: https://doi.org/10.2147/JHC.S61146
- [6]. Tang, C., He, C., Wang, D., Guo, J., Yin, X., Ye, H., Wu, L., Zhang, Y., Zeng, S., Zeng, X., Liu, C., Chen, J., & Fang, C. (2025). Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma. Nature Communications, 16(1), 10096. https://doi.org/10.1038/s41467-025-65056-9. DOI: https://doi.org/10.1038/s41467-025-65056-9
- [7]. Cheng, A.-L., Hsu, C.-H., Shen, Y.-C., Shao, Y.-Y., & Hsu, C. (2014). Sorafenib in advanced hepatocellular carcinoma: Current status and future perspectives. Journal of Hepatocellular Carcinoma, 85. https://doi.org/10.2147/JHC.S45040. DOI: https://doi.org/10.2147/JHC.S45040
- [8]. Gong, L., Giacomini, M. M., Giacomini, C., Maitland, M. L., Altman, R. B., & Klein, T. E. (2017). PharmGKB summary: Sorafenib pathways. Pharmacogenetics and Genomics, 27(6), 240-246. https://doi.org/10.1097/FPC.0000000000000279. DOI: https://doi.org/10.1097/FPC.0000000000000279
- [9]. Dahiya, M., & Dureja, H. (2022). Sorafenib for hepatocellular carcinoma: Potential molecular targets and resistance mechanisms. Journal of Chemotherapy, 34(5), 286-301. https://doi.org/10.1080/1120009X.2021.1955202. DOI: https://doi.org/10.1080/1120009X.2021.1955202
- [10]. Kianamiri, S., Shokri, E., Maleki, P., Soudi, S., Soltaninejad. H., & Sadeghizadeh, M. (2025). Novel curcumin nanocarrier for targeting drug delivery of mitochondria proves efficacy in in vivo experiments on hepatocellular carcinoma mice models. Scientific Reports, 15(1), 35114. https://doi.org/10.1038/s41598-025-19147-8. DOI: https://doi.org/10.1038/s41598-025-19147-8
- [11]. R. V., Shetty, M. P., S, S., Shenoy, R. P., Mutalik, S., & Bharati, S. (2025). Arabinogalactan-Functionalized Gold Nanoparticles Demonstrated Remarkable Anticancer Therapeutic Effect against Hepatocellular Carcinoma. Molecular Pharmaceutics, 22(11), 6646-6657. https://doi.org/10.1021/acs.molpharmaceut.5c00598. DOI: https://doi.org/10.1021/acs.molpharmaceut.5c00598
- [12]. Pusta, A., Tertis, M., Ciocan, B., Turcu, R., Crăciunescu, I., Diculescu, V. C., Stan, G. E., Bulat, S., Porfire, A., Petru, A.-E., Fizeşan, I., Mirel, S., & Cristea, C. (2025). Aptamer-Modified Magnetic Nanoparticles as Targeted Drug Delivery Systems for Hepatocellular Carcinoma. Pharmaceutics, 17(10), 1292. https://doi.org/10.3390/pharmaceutics17101292. DOI: https://doi.org/10.3390/pharmaceutics17101292
- [13]. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., ... Trail, P. A. (2004). BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Research, 64(19), 7099-7109. https://doi.org/10.1158/0008-5472.CAN-04-1443. DOI: https://doi.org/10.1158/0008-5472.CAN-04-1443
- [14]. Mao, W., Shao, M., Gao, P., Ma, J., Li, H., Li, G., Han, B., & Yuan, C. (2012). The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib. Acta Pharmacologica Sinica, 33(10), 1311-1318. https://doi.org/10.1038/aps.2012.76. DOI: https://doi.org/10.1038/aps.2012.76
- [15]. Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., & Carter, C. (2006). Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5. Cancer Research, 66(24), 11851-11858. https://doi.org/10.1158/0008-5472.CAN-06-1377. DOI: https://doi.org/10.1158/0008-5472.CAN-06-1377
- [16]. Qi, D., Qin, Y., Zhu, H., Li, Y., & Han, S. (2025). Resistance of first-line targeted drugs in hepatocellular carcinoma: The epigenetic regulation mechanisms. Cell Death & Disease, 16(1), 875. https://doi.org/10.1038/s41419-025-08105-x. DOI: https://doi.org/10.1038/s41419-025-08105-x
- [17]. Edginton, A. N., Zimmerman, E. I., Vasilyeva, A., Baker, S. D., & Panetta, J. C. (2016). Sorafenib metabolism, transport, and enterohepatic recycling: Physiologically based modeling and simulation in mice. Cancer Chemotherapy and Pharmacology, 77(5), 1039-1052. https://doi.org/10.1007/s00280-016-3018-6. DOI: https://doi.org/10.1007/s00280-016-3018-6
- [18]. Zou, Y., Wan, X., Zhou, Q., Zhu, G., Lin, S., Tang, Q., Yang, X., & Wang, S. (2025). Mechanisms of drug resistance in hepatocellular carcinoma. Biological Procedures Online, 27(1), 19. https://doi.org/10.1186/s12575-025-00281-6. DOI: https://doi.org/10.1186/s12575-025-00281-6
- [19]. Vandamme. (2008). Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. International Journal of Nanomedicine, 1. https://doi.org/10.2147/IJN.S1045. DOI: https://doi.org/10.2147/IJN.S1045
- [20]. Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012). Nanoparticles as drug delivery systems. Pharmacological Reports, 64(5), 1020-1037. https://doi.org/10.1016/S1734-1140(12)70901-5. DOI: https://doi.org/10.1016/S1734-1140(12)70901-5
- [21]. Zhu, Y., Ge, D., Wang, J., Sun, H., Li, W., & Ren, H. (2025). Emerging nanomedicine for liver diseases treatment. Journal of Nanobiotechnology, 23(1), 786. https://doi.org/10.1186/s12951-025-03832-x. DOI: https://doi.org/10.1186/s12951-025-03832-x
- [22]. Zhang, L., Gong, Zhang, Ma, Zhang, & Shen. (2013). Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. International Journal of Nanomedicine, 1517. https://doi.org/10.2147/IJN.S43263. DOI: https://doi.org/10.2147/IJN.S43263
- [23]. Zheng, N., Liu, W., Li, B., Nie, H., Liu, J., Cheng, Y., Wang, J., Dong, H., & Jia, L. (2019). Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib. Journal of Experimental & Clinical Cancer Research, 38(1), 232. https://doi.org/10.1186/s13046-019-1216-x. DOI: https://doi.org/10.1186/s13046-019-1216-x
- [24]. Ling, J., Jiang, Y., Yan, S., Dang, H., Yue, H., Liu, K., Kuang, L., Liu, X., & Tang, H. (2022). A novel pH- and glutathione-responsive drug delivery system based on in situ growth of MOF199 on mesoporous organic silica nanoparticles targeting the hepatocellular carcinoma niche. Cancer Nanotechnology, 13(1), 32. https://doi.org/10.1186/s12645-022-00139-6. DOI: https://doi.org/10.1186/s12645-022-00139-6
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Luis Roberto Galindo Mendez, Diana Ginette Zarate Triviño
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
